ContraFect_LOGO_Web.jpg
ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference
September 22, 2021 07:30 ET | ContraFect Corporation
YONKERS, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update
August 13, 2021 07:30 ET | ContraFect Corporation
Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the Company’s DLA portfolio Continued patient enrollment in ongoing...
ContraFect_LOGO_Web.jpg
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021 07:30 ET | ContraFect Corporation
Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase...
ContraFect_LOGO_Web.jpg
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
May 03, 2021 07:30 ET | ContraFect Corporation
YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook
March 11, 2021 16:05 ET | ContraFect Corporation
BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections Results from the Phase 3 DISRUPT study interim...
ContraFect_LOGO_Web.jpg
ContraFect Announces Appointment of Dr. Jane F. Barlow to Board of Directors
February 11, 2021 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...
ContraFect_LOGO_Web.jpg
ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update
November 13, 2020 08:33 ET | ContraFect Corporation
CARB-X and Cystic Fibrosis Foundation grants provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections Initiated expanded access program with exebacase for the...
ContraFect_LOGO_Web.jpg
ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients
October 26, 2020 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect_LOGO_Web.jpg
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
August 14, 2020 07:30 ET | ContraFect Corporation
Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase Successful public equity offering,...
ContraFect_LOGO_Web.jpg
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
July 20, 2020 07:30 ET | ContraFect Corporation
YONKERS, N.Y., July 20, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...